Tag Archives: biotech industry

My family farm isn’t under “corporate control”

Brian Scott

On CNN’s blog, “Eatocracy”, Indiana farmer Brian Scott challenges the myth that farmers are slaves to “Big Ag” and explains from first-hand experience how biotech seed contracts work. In his blog post titled, “My family farm isn’t under ‘corporate control’“, Scott posts a copy of an actual technology agreement he signed, and explains how such agreements help him to operate the farm in the manner his family chooses. Among the requirements of technology and stewardship Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

What’s Behind the Rise in Executive Liability Insurance Prices?

Joe Haltman

What do gas, milk, bacon, electricity and now your Directors and Officers Liability Insurance coverage have in common? It may sound like the start of a bad joke but, in fact, they’re all goods or services that cost more than they used to. Some of you may have noticed that the price of Directors and Officers Liability, or D&O Insurance, is going up. Companies and organizations across the biotechnology sector are seeing price increases, with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Anti-Biotech Activist Changes Sides: “I discovered science”

Mark Lynas

If you missed last week’s report from the Oxford Farming Conference, Mark Lynas, the British writer and environmentalist who once helped drive Europe’s movement against biotech crops, apologized for those actions and embraced the technology as a vital tool for ending hunger and conserving the environment. The change of heart was widely reported in many mainstream outlets such as The New York Times, Los Angeles Times, Forbes, Discover magazine, Slate magazine and Science 2.0, among others. Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

Drug Manufacturing

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug development. Harder:  Drug development is challenging.  It takes over 10 years and more than $1 billon to bring a therapy through the product pipeline, from the research lab to clinical trials to FDA approval to prescription to patients suffering from the disease. The FDA approved over 30 innovative drugs last year, including more than 10 new treatments for cancer—a good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,